In a stark reminder of the federal government’s enhanced capability to rapidly freeze the assets of its enforcement targets, the U.S. District Court for the Central District of California has authorized the seizure of more than $2 million from Expert Wound Care PC, a Pasadena-based advanced wound care clinic. The civil forfeiture action, announced by the Department of Justice, highlights a sophisticated, data-driven investigation into an alleged Medicare billing scheme involving skin graft substitute application procedures that federal law enforcement contends were never actually performed.

The Billing Anomalies Underlying the Alleged Scheme

According to federal court affidavits, between September 2025 and April 2026, Expert Wound Care submitted $46.6 million in claims to Medicare for skin substitute products and wound care services purportedly rendered to just 78 beneficiaries. Medicare approved and disbursed just over $34 million on those claims before data analytics triggered an immediate enforcement intervention.

The government’s case relies heavily on statistical benchmarking and aberrant billing patterns that deviated aggressively from national healthcare provider norms:

  • Explosive Billing Growth: The clinic’s monthly Medicare billing skyrocketed from a baseline of $4,975 in July 2025 to approximately $33 million in December 2025 alone.
  • Inflated Per-Claim Costs: Between July 2025 and March 2026, Expert Wound Care averaged $37,449 in allowed amounts per skin substitute graft claim—more than double the national provider average of $16,837 tracked during the first half of 2025.
  • Disproportionate Utilization: The clinic reported that 38.5% of its total beneficiary base received high-cost skin substitute grafts, more than six times the national average of 6%. Furthermore, skin substitute grafts constituted 63% of the clinic's total claims, roughly nine times the national norm.

Expert Wound Care PC is alleged to have billed Medicare approximately $2.6 million, of which it received over $2 million, for just a single beneficiary. Prosecutors presented evidence to the court that this patient never received skin grafts or was provided any home services during December 2025—a month in which the clinic submitted 27 separate claims on his behalf.

The Broader Landscape: The White House Anti-Fraud Task Force and California Enforcement

This swift asset seizure is not an isolated regulatory event; it represents the operational deployment of the DOJ’s newly formed National Fraud Enforcement Division. This division works in lockstep with the White House’s Task Force to Eliminate Fraud, a whole-of-government initiative chaired by the Vice President to eliminate waste and systemic abuse within federal benefit programs.

California, particularly the Central District, has emerged as a primary testing ground for these intensified enforcement dynamics. The region has seen a coordinated multi-agency surge involving Homeland Security Investigations (HSI) and the Department of Health and Human Services Office of Inspector General (HHS-OIG). Recent West Coast takedowns have aggressively targeted high-reimbursement sectors—including multi-million dollar hospice scams, diagnostic laboratory upcoding, and high-volume DME schemes.

Healthcare Providers Beware: The Shift to Pre-Indictment Interventions

The Expert Wound Care case underscores a critical paradigm shift in federal enforcement doctrine: the government is no longer waiting for the conclusion of an audit or lengthy False Claims Act (FCA) litigation to disrupt suspected fraud. Instead, federal regulators are resorting to aggressive financial and administrative interventions at much earlier stages of the investigative lifecycle.

This pre-indictment seizure tactic mirrors the aggressive use of immediate payment suspensions deployed against California’s hospice industry. In both contexts, the strategy is clear: use advanced data analytics to detect anomalies, bypass months of formal discovery, and move instantly to choke off corporate capital before criminal indictments are ever unsealed.

For providers utilizing high-reimbursement modalities like bioengineered skin substitutes, cellular therapies, or advanced wound care products, stringent compliance is paramount. Entities must ensure that documentation clearly justifies medical necessity and the CPT codes applied, reflects accurate utilization metrics, and avoids rapid, unbacked spikes in billing volume that invariably trigger federal task force scrutiny.